老年急性髓系白血病的治疗进展
摘要
关键词
全文:
PDF参考
N Howlader, AM Noone, M Krapcho, et al. SEER Cancer Statistics Review[J].Vintage Populations, 2012(7):1975-2009.
Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study[J]. Haematologica, 2012,97(12):1916-1924.
Castaigne S, Pautas C, T erre C et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, Phase III study[J]. Lancet, 2012(4):1508-1516.
Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl[J]. Med, 2017(8):3342-3348.
Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and dau-norubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed second-ary acute myeloid leukemia.J Clin Oncol Off[J]. Am Soc ClinOncol, 2018,36(26):2684-2692.
Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or with-out glasdegib in patients with newly diagnosed acute myeloid 103 Page 12 of 14 Curr Oncol Rep (2020) 22:103 leukemia or high-risk myelodysplastic syndrome[J]. Leukemia, 2019,33(2):379-389.
Stein EM, Dinardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia[J]. Blood, 2017,130(6):722-731.
Fan B, Le K, Manyak E, et al. Longitudinal pharmacokinetic/pharmacodynamic profile of AG-120, a potent inhibitor of the IDH1 mutant protein, in a Phase 1 study of IDH1-mutant advanced hematologic malignancies[J]. Blood, 2015(23):1310.
DOI: http://dx.doi.org/10.12345/yzlcyxzz.v4i6.7964
Refbacks
- 当前没有refback。
![Creative Commons License](http://licensebuttons.net/l/by-nc/4.0/88x31.png)
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。